Melbourne, Australia; 5 April 2016: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it will present this week at the Bio-Europe^® conference in Stockholm. At the conference Starpharma will also be conducting partnering discussions with pharmaceutical companies for VivaGel^® BV, DEP^TM and other parts of Starpharma’s portfolio.

Bio-Europe^® is Europe’s largest partnering conference for biotechnology and life sciences companies, attracting more than 2,300 attendees representing more than 1,300 companies from 53 countries. Dr Tony Eglezos, VP Business Development, will be presenting for Starpharma at the Enabling Technologies session. Attendees at the conference include many of the world’s leading pharmaceutical companies including Roche, Sanofi, Takeda, Pfizer, Genentech, Lilly and Amgen.

Starpharma’s presentation primarily focuses on the DEP^TM drug delivery platform and includes new data on DEP^TM cabazitaxel, which recently demonstrated complete and sustained tumour regression in a breast cancer model. DEP™ cabazitaxel is Starpharma’s dendrimer-enhanced, water soluble (detergent free) version of the leading cancer drug, Jevtana^® (cabazitaxel). The presentation also contains brief updates on various other parts of Starpharma’s portfolio including recent positive data for the VivaGel^® active (SPL7013) in viral conjunctivitis.

View Presentation: Bio_Europe_2016_presentation.pdf (pdf file, 1MB)